New lupus drug RO7507062 enters first human safety trial
NCT ID NCT05835986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7507062
What this could lead to
If this drug is safe and shows promise, it could lead to a new treatment option for people with systemic lupus erythematosus.
What could go wrong
This is a very early, first-in-human study focused on safety, not effectiveness. The drug may not work or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CREA Hospital Mexico Americano
Guadalajara, Jalisco, 44620, Mexico
-
Centre For Human Drug Research
Leiden, 2333, Netherlands
-
Chang Gung Medical Foundation - Linkou
Taoyuan, 333, Taiwan
-
Charité Research Organisation GmbH
Berlin, 10117, Germany
-
Chung Shan Medical University Hospital
Taichung, 40201, Taiwan
-
Clinica De La Costa
Barranquilla, 080020, Colombia
-
Clínica San Juan Bautista CSJB
Lima, 15431, Peru
-
FARMOVS (Pty) Ltd
Bloemfontein, 9301, South Africa
-
Groupe Hospitalier Pitie-Salpetriere
Paris, 75651, France
-
Hospital Angeles De Lindavista
Mexico City, Mexico CITY (federal District), 07760, Mexico
-
Hospital General De Mexico
Mexico City, Mexico CITY (federal District), 6726, Mexico
-
Hospital General Universitario Gregorio Marañon
Madrid, 28007, Spain
-
Hospital Pablo Tobon Uribe
Medellín, 050034, Colombia
-
Hospital Umum Sarawak
Kuching, 93586, Malaysia
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
-
Hôpital Saint Eloi
Montpellier, 34295, France
-
Oncomedica S.A.
Montería, 230002, Colombia
-
Ramathibodi Hospital, Mahidol Uni
Bangkok, 10400, Thailand
-
UCL Hospital NHS Trust
London, NW1 2PG, United Kingdom
-
Universitätsklinikum Duesseldorf
Düsseldorf, 40225, Germany
-
Uniwersytecki Szpital Kliniczny w Poznaniu
Późna, 61-848, Poland
-
Wojskowy Instytut Medyczny- Panstwowy Instytut Badawczy
Warsaw, 04-141, Poland